Currently Viewing:
European Committee for Research and Treatment in Multiple Sclerosis 2013

Fred Lublin, MD, Examines Research and Key Takeaways from ECTRIMS 2013

In this video, Fred Lublin, MD, Saunders Family professor of neurology, director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, discussed the results of his poster presentation, Natalizumab Reduces the Disabling Amplitude of Multiple Sclerosis Relapses and Improves Post-relapse Residual Disability.
In this video, Fred Lublin, MD, Saunders Family professor of neurology, director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, discussed the results of his poster presentation, “Natalizumab Reduces the Disabling Amplitude of Multiple Sclerosis Relapses and Improves Post-relapse Residual Disability.” This poster compares the recovery rate of patients on natalizumab versus those receiving placebo. “Not only do disease modifying therapies like natalizumab cut down on the number of exacerbations, but they cut down on the severity of the exacerbation and improve the chances of having a better recovery from any given exacerbation,” said Dr Lublin.

Dr Lublin said that an interesting topic addressed at ECTRIMS 2013 was identifying the merits of an escalation therapy approach as opposed to an induction therapy approach to treatment. “The big hope for the future right now is to develop disease-modifying therapies that can affect progressive disease,” concluded Dr Lublin.

 
 


 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up